EVALUATION OF CYCLOPHOSPHAMIDE WITH PEPTIDE VACCINES IN PARTICIPANTS W/MELANOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究旨在评估由I类和II类限制性多肽组成的疫苗在晚期黑色素瘤患者中的免疫原性。本研究的目的是：(A)测试黑色素瘤来源的II型MHC限制性辅助肽是否能增强CD8+T细胞反应；(B)测试黑色素瘤来源的II型MHC限制性辅助肽是否影响CD8+T细胞反应的持久性；以及(C)评估环磷酰胺对肽疫苗免疫原性的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study was designed to assess the immunogenicity of a vaccine comprised of class I- and class II-restricted peptides in patients with advanced melanoma. The objectives of this study are to (a) test whether inclusion of melanoma-derived class II MHC-restricted helper peptides augments CD8+ T-cell responses, (b) test whether inclusion of melanoma-derived class II MHC-restricted helper peptides affects the persistence of CD8+ T-cell responses, and (c) evaluate the effects of cyclophosphamide on the immunogenicity of a peptide-based vaccine.